Interferon Gamma,but not Calcitriol Improves the Osteopetrotic Phenotypes in ADO2 Mice |
| |
| Authors: | Imranul Alam Amie K Gray Dena Acton Rita L Gerard‐O'Riley Austin M Reilly Michael J Econs |
| |
| Affiliation: | 1. Medicine, Indiana University School of Medicine, IN, USA;2. Medical and Molecular Genetics, Indiana University School of Medicine, IN, USA |
| |
| Abstract: | ADO2 is a heritable osteosclerotic disorder that usually results from heterozygous missense dominant negative mutations in the chloride channel 7 gene (CLCN7). ADO2 is characterized by a wide range of features and severity, including multiple fractures, impaired vision due to secondary bony overgrowth and/or the lack of the optical canal enlargement with growth, and osteonecrosis/osteomyelitis. The disease is presently incurable, although anecdotal evidence suggests that calcitriol and interferon gamma‐1b (IFN‐G) may have some beneficial effects. To identify the role of these drugs for the treatment of ADO2, we utilized a knock‐in (G213R mutation in Clcn7) ADO2 mouse model that resembles the human disease. Six‐week‐old ADO2 heterozygous mice were administered vehicle (PBS) or calcitriol or IFN‐G 5 times per week for 8 weeks. We determined bone phenotypes using DXA and μCT, and analyzed serum biochemistry and bone resorption markers. ADO2 mice treated with all doses of IFN‐G significantly (p<0.05) attenuated the increase of whole body aBMD and distal femur BV/TV gain in both male and female compared to the vehicle group. In contrast, mice treated with low and medium doses of calcitriol showed a trend of higher aBMD and BV/TV whereas high dose calcitriol significantly (p<0.05) increased bone mass compared to the vehicle group. The calcium and phosphorus levels did not differ between vehicle and IFN‐G or calcitriol treated mice; however, we detected significantly (p<0.05) elevated levels of CTX/TRAP5b ratio in IFN‐G treated mice. Our findings indicate that while IFN‐G at all doses substantially improved the osteopetrotic phenotypes in ADO2 heterozygous mice, calcitriol treatment at any dose did not improve the phenotype and at high dose further increased bone mass. Thus, use of high dose calcitriol therapy in ADO2 patients merits serious reconsideration. Importantly, our data support the prospect of a clinical trial of IFN‐G in ADO2 patients. |
| |
| Keywords: | Bone mineral density ADO2 Calcitriol Interferon‐gamma Osteopetrosis |
|
|
